Linked Life Data

19422329

Source:http://linkedlifedata.com/resource/pubmed/id/19422329

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-5-8
pubmed:abstractText
While clinical protocols have been developed to allow for successful kidney transplantation in patients with high levels of donor-specific alloantibody (DSA), significant limitations still exist including high rates of early humoral rejection and decreased long-term graft survival compared to conventional transplants. A better understanding of the mechanisms of alloantibody production at baseline and at various phases posttransplant would be an important step toward the development of improved therapeutic approaches. The goal of this review is to outline recent studies regarding antibody production in general and specific studies that illustrate what is known about alloantibody production in sensitized patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1600-6143
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
998-1005
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Mechanisms of alloantibody production in sensitized renal allograft recipients.
pubmed:affiliation
Division of Transplantation, Department of Surgery, Mayo Clinic, Rochester, MN, USA. stegall.mark@mayo.edu
pubmed:publicationType
Journal Article, Review